Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV Inhibitor
HI-253 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase, exhibiting significant antiviral activity against both resistant and sensitive strains of HIV-1. This compound serves as a valuable tool for research focused on HIV treatment and the mechanisms of viral resistance, making it essential for studies aimed at developing new therapeutic strategies against HIV. -
HIV Inhibitor
[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) functions as a selective inhibitor of HIV-1 by obstructing the interaction between the virus and CD4 molecules. This compound demonstrates significant antiviral activity by effectively inhibiting viral infection and cell fusion. Research applications include studies focused on HIV treatment mechanisms and exploration of CD4 receptor interactions, with complete inhibition of fusion formation observed at a concentration of 25 μM. -
HIV Inhibitor
HIV-1 protease-IN-1 is a highly potent inhibitor of the HIV-1 protease, exhibiting an IC50 of 90 pM. This compound demonstrates significant antiviral activity, with EC50 values of 89 nM against the B-HIV strain and 13.59 nM against the C-HIV strain ZM246, as well as an impressive EC50 of 8.23 nM against the C-HIV strain Indie. HIV-1 protease-IN-1 serves as a valuable tool for research and development in HIV treatment strategies and antiviral drug discovery. -
HIV-1 gp120 Inhibitor
gp120-IN-1 is a potent inhibitor targeting the HIV-1 gp120 protein. It demonstrates significant anti-HIV-1 activity with an IC50 value of 2.2 µM, while exhibiting a CC50 of 100.90 µM in SUP-T1 cells, indicating dose-dependent cytotoxicity. This compound effectively inhibits gp120-mediated viral entry into host cells, making it a valuable tool for research in HIV therapeutics and virology studies. -
HIV Inhibitor
Tenofovir-C3-O-C12-trimethylsilylacetylene ammonium is a potent HIV inhibitor that demonstrates significantly prolonged half-life values compared to tenofovir in human liver microsomes. This compound exhibits robust anti-HIV activity in vitro and shows enhanced pharmacokinetic properties in vivo. Additionally, it serves as a click chemistry reagent featuring an alkyne group, which allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating various research applications in medicinal chemistry and drug development. -
HIV-1 Protease Inhibitor
CGP 53437 is a potent HIV-1 protease inhibitor, exhibiting a Ki value of 0.2 nM. This compound effectively inhibits HIV replication, making it a valuable tool for research focused on HIV pathogenesis and antiviral therapy development. Its oral bioactivity supports studies in pharmacokinetics and therapeutic interventions against HIV. -
Reverse Transcriptase Inhibitor
BILR 355 is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. This compound demonstrates potent inhibition of viral replication, making it a valuable tool for research on HIV infections and the development of antiviral therapies. BILR 355's selectivity and effectiveness in disrupting reverse transcription make it an important reagent for studying HIV biology and drug resistance. -
HIV Inhibitor
(-)-6-Aminocarbovir is an antiviral compound that acts as a potent inhibitor of HIV replication. It demonstrates significant biological activity against the virus, making it a valuable tool in HIV research. This reagent is applicable for studies focusing on viral infections and the development of antiviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
U 88204 is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 value of 0.25 μM. This compound effectively blocks the replication of HIV-1 in infected cells, making it a valuable tool for research focused on HIV infection and acquired immunodeficiency syndrome (AIDS). Its specificity and efficacy facilitate studies aimed at understanding the mechanisms of viral replication and the development of antiviral therapies. -
HIV Inhibitor
VCH-286 is a selective CCR5 inhibitor that demonstrates significant in vitro activity against HIV-1. This compound effectively blocks the CCR5 co-receptor, preventing viral entry into host cells. VCH-286 is particularly useful for research applications focused on understanding HIV-1 pathogenesis and developing therapeutic strategies targeting CCR5-mediated viral infections. -
CCR5 Inhibitor
CMPD167 is a selective CCR5 inhibitor that exerts its antiviral effects by blocking the CCR5 receptor, which is critical for the entry of certain viruses into host cells. This compound demonstrates potent antiviral activity in vitro, making it a valuable tool for research on viral infections, particularly in studies related to HIV. CMPD167 can facilitate investigations into CCR5-related pathways and the development of therapeutic strategies targeting viral entry mechanisms. -
Nucleoside Reverse Transcriptase Inhibitor
Amdoxovir is a nucleoside reverse transcriptase inhibitor that acts as a prodrug of dioxolane guanosine. It demonstrates efficacy against both wild-type and nucleoside reverse transcriptase inhibitor-resistant HIV strains. Amdoxovir is utilized in research related to HIV/AIDS, providing insight into antiviral mechanisms and potential therapeutic strategies. -
HIV-1 Inhibitor
HIV-1 inhibitor-61 is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an EC50 of 0.07 nM in NL4-3 wild-type MT-4 cells. This compound effectively disrupts viral replication, making it a valuable tool in HIV research and the development of antiviral therapies. Its high efficacy positions it as an essential reagent for studying HIV-1 pathogenesis and potential therapeutic interventions. -
HIV-1 Reverse Transcriptase Inhibitor
BRN3OMe is a potent inhibitor of HIV-1 reverse transcriptase, specifically targeting the enzyme essential for the replication of the HIV-1 virus. This compound demonstrates significant antiviral activity, making it a valuable tool in the study of HIV replication and the development of antiviral agents. Researchers may utilize BRN3OMe to explore mechanisms of inhibition and therapeutic applications in HIV treatment strategies. -
HIV Protease Inhibitor
JE-2147 is a potent dipeptide inhibitor of HIV protease, exhibiting a Ki value of 0.33 nM for HIV-1 protease. This compound demonstrates effective antiviral activity against a broad range of HIV strains, including HIV-1, HIV-2, simian immunodeficiency virus, and various clinical isolates of HIV-1 in vitro. JE-2147 serves as a valuable tool for research into HIV protease inhibition and the development of antiretroviral therapies. -
HIV Inhibitor
HIV-IN-4 is a potent inhibitor of HIV, targeting key viral replication processes. This compound demonstrates significant anti-HIV activity, making it a valuable tool for research into HIV therapeutics and antiviral strategies. Its efficacy supports investigations into mechanisms of resistance and the development of novel treatment approaches for HIV-infected individuals. -
HIV-1 Inhibitor
18A is a reversible broad-spectrum inhibitor of HIV-1 that targets the envelope protein (Env) to block viral entry. This compound demonstrates significant inhibitory activity against various HIV-1 strains, making it a valuable tool for HIV research and therapeutic development. Its mechanism of action positions 18A as a potential candidate for studying viral resistance and the development of novel antiviral strategies. -
HIV-1 Reverse Transcriptase Ribonuclease H Inhibitor
GSK5750 is a specific and potent inhibitor of HIV-1 reverse transcriptase ribonuclease H, exhibiting an IC50 value of 0.33 μM. This compound functions through a metal-ion chelation mechanism at the RNase H active site. GSK5750 is valuable for research into HIV replication and the development of antiviral strategies targeting reverse transcriptase. -
HIV Inhibitor
HIV p17 Gag (77-85) is an HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitope that serves as an HIV inhibitor. This peptide is critical for studies aimed at understanding immune responses to HIV infection and developing immunotherapeutic strategies. It can be employed to evaluate T cell responses and facilitate vaccine design within HIV research applications. -
HIV-1 Inhibitor
(±)-PM 92131 is a non-nucleoside inhibitor targeting HIV-1. It demonstrates significant anti-HIV-1 activity with IC50 values of 45.7 μM and 53.8 μM against the HIV-1 RF strain, as assessed in XTT cytoprotection and syncytium-forming assays, respectively. This compound is suitable for research applications focused on HIV infections and the development of antiviral strategies. -
Non-nucleoside Reverse Transcriptase Inhibitor
DC20 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1, exhibiting an EC50 of 0.004 μM against the HIV-1IIIB strain. This compound demonstrates significant antiviral activity, making it a valuable tool in the study and treatment of HIV infections. Its efficacy positions DC20 as a critical reagent for research in antiviral drug development and mechanisms of HIV resistance. -
HIV inhibitor
F9170 is an amphipathic peptide that serves as an inhibitor of HIV-1, effectively inactivating the virus by targeting the conserved cytoplasmic tail of the HIV-1 envelope protein. By disrupting the integrity of the viral membrane, F9170 demonstrates strong antiviral activity. Additionally, this compound possesses the ability to cross the blood-brain barrier, making it a relevant candidate for research applications focused on HIV treatment, particularly in the context of central nervous system involvement. -
Non-nucleoside Reverse Transcriptase Inhibitor
RDEA 806 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates potent inhibitory activity against both wild-type and NNRTI-resistant HIV-1 strains, with an EC50 of 3.05 nM. This compound's selective action on reverse transcriptase makes it a valuable tool for studying HIV replication and developing antiviral therapies. Research applications include evaluating resistance patterns and assessing the efficacy of combination treatments in HIV research. -
HIV-1 Capsid Inhibitor
HIV-1 Capsid Inhibitor 1 targets the HIV-1 capsid, demonstrating significant antiviral activity with an EC50 value of 3.13 µM. This compound serves as a valuable tool in HIV research, providing insights into viral replication mechanisms and potential therapeutic interventions. Its ability to inhibit viral capsid formation makes it a critical reagent for the study of HIV-1 pathogenicity and the development of novel antiviral strategies. -
HIV Inhibitor
Mer-NF5003E is a non-nucleoside reverse transcriptase inhibitor targeting HIV-1 reverse transcriptase, with an EC50 value of 50 μM. This compound demonstrates inhibitory activity against both wild-type HIV-1 and various NNRTI-resistant strains, including K103N and Y181C. Mer-NF5003E serves as a valuable tool for research focused on HIV infections and the development of therapeutic strategies to combat resistant viral strains. -
HIV-1 Reverse Transcriptase Inhibitor
Melanochromone is an inhibitor of HIV-1 reverse transcriptase, demonstrating significant anti-HIV-1 activity. This compound is utilized in research focusing on HIV-1 infection and its mechanisms, contributing to the understanding of viral replication and potential therapeutic interventions. -
HIV-1 RT Inhibitor
Nigranoic acid is a triterpenoid that inhibits HIV-1 reverse transcriptase, presenting potential applications in antiviral research. Additionally, Nigranoic acid demonstrates neuroprotective effects by engaging the PARP/AIF signaling pathway, as evidenced in cerebral ischemia-reperfusion models. This dual activity positions Nigranoic acid as a valuable compound for further investigation in HIV treatment and neuroprotection studies. -
HIV Inhibitor
12-Oxocalanolide A is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 of 2.8 μM and an EC50 of 12 μM. This compound serves as an analogue of Calanolide, demonstrating significant antiviral activity against human immunodeficiency virus type 1. It is valuable for research in virology and the development of anti-HIV therapeutics. -
HIV Protease Inhibitor
CGP 53820 is a potent inhibitor of HIV protease, demonstrating Ki values of 9 nM for HIV-1 protease and 53 nM for HIV-2 protease. This compound effectively disrupts the enzymatic activity critical for the replication of HIV, making it a valuable tool in AIDS research and the study of antiretroviral therapies. Its specificity and efficacy support investigations into HIV resistance and the development of novel therapeutic strategies. -
HIV Inhibitor
HIV-1 Inhibitor-37 is a potent inhibitor of HIV-1, targeting viral replication pathways. It has demonstrated efficacy in reversing latency, presenting valuable potential for development as a novel therapeutic agent. This compound is suitable for research applications focused on HIV latency and the mechanisms of viral eradication. -
HIV-1 Capsid Protein Inhibitor
I-XW-053 sodium is an inhibitor of the HIV-1 capsid protein, demonstrating significant antiviral activity against HIV-189BZ167 with an IC50 value of 164.2 μM. This compound effectively disrupts the interaction between the N-terminal domains of the capsid protein, specifically at the NTD-NTD interface, exhibiting micromolar affinity. I-XW-053 is a valuable tool for research aimed at understanding HIV replication and developing therapeutic strategies against HIV infection. -
HIV-1 Capsid Inhibitor
HIV-1 Inhibitor-17 is a potent HIV-1 capsid inhibitor, demonstrating significant antiviral activity with an EC50 value of 2.57 μM against the HIV-1 NL4-3 strain. This compound exhibits certain cytotoxicity, with a CC50 value greater than 8.55 in MT-4 cells. It is valuable for research applications aimed at understanding HIV-1 replication and developing effective therapeutic strategies. -
Reverse Transcriptase Inhibitor
PNU-103657 is an orally active reverse transcriptase inhibitor, demonstrating an IC50 value of 0.51 μM against wild-type enzyme. This compound exhibits significant antiviral activity, making it a valuable tool in research targeting viral infections, particularly in the context of HIV and related immune system disorders. -
HIV-1 Reverse Transcriptase Inhibitor
DPC-082 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates significant antiviral activity, with an IC90 of 2.0 nM against wild-type RF virus. Additionally, DPC-082 effectively inhibits a variety of single and multiple amino acid substituted HIV-1 mutant strains, making it a valuable tool for research into HIV resistance mechanisms and therapeutic development. -
HIV Inhibitor
Fostemsavir sodium is an HIV-1 attachment inhibitor that demonstrates antiviral activity against multidrug-resistant strains of HIV-1. This compound not only hinders viral entry but also exhibits potential effects in reducing markers associated with monocyte activation and coagulation abnormalities. Its applications include research on HIV pathogenesis, treatment resistance, and the immune response in HIV-infected individuals. -
CCR5 inhibitor
CB-0821 is a high-affinity CCR5 inhibitor with a Ki value of 0.04 nM. It effectively binds to the hydrophobic pocket of the CCR5 protein, disrupting the interactions between viral proteins and CCR5, which inhibits viral entry into cells. This compound is poised for use in anti-HIV research applications, facilitating studies on viral tropism and potential therapeutic strategies. -
HIV-1 Protease Inhibitor
Mozenavir is a potent inhibitor of HIV-1 protease, exhibiting a Ki value of 0.3 nM. By obstructing the cleavage and processing of viral polyproteins, Mozenavir effectively inhibits the replication and maturation of HIV-1. This compound holds significant promise for advancing research on HIV infection and its associated therapeutic strategies. -
HIV Inhibitor
HIV-IN-13 is a potent HIV inhibitor that effectively targets the virus in CEM-SS cells with an EC50 of 1.38 μM. It exhibits antiviral activity against various HIV strains in human peripheral blood mononuclear cells (hPBMCs), demonstrating EC50 values ranging from 2.01 to 10.7 μM, while maintaining low cellular toxicity (TC50 > 100 μM). This compound is suitable for research applications focused on HIV infection and its mechanisms of action. -
HIV Inhibitor
HIV-1 inhibitor-57 is a potent HIV-1 inhibitor that targets reverse transcriptase (RT). Demonstrating activity against both wild-type and several prevalent non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, it exhibits effective EC50 values between 0.024 to 0.0010 μM. This compound enhances binding through additional interactions with critical residues in the HIV-1 RT binding site, making it a valuable tool for HIV research and antiviral drug development. -
Reverse Transcriptase Inhibitor
Niglizin is a noncompetitive inhibitor of reverse transcriptase, demonstrating significant efficacy in suppressing HIV replication. This compound exhibits a synergistic effect when used in conjunction with Zidovudine, enhancing its antiviral activity. Niglizin is valuable for research applications focused on HIV infection and the development of antiretroviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-31 is a potent inhibitor targeting the HIV-1 virus. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for AIDS research. Its effectiveness in inhibiting viral replication allows for the investigation of novel therapeutic approaches in the treatment of HIV infection. -
HIV-1 Inhibitor
Rhuscholide A is a benzofuran lactone that primarily inhibits HIV-1 activity. It exhibits significant antiviral potency, with an EC50 value of 1.62 μM. This compound is useful in research focused on the development of HIV therapies and studying viral replication mechanisms. -
HIV Inhibitor
Aureothin is a natural polyketide that functions as an HIV inhibitor, exhibiting an IC50 of 5.3 nM. This compound demonstrates significant antiviral activity, making it a valuable tool in HIV research. Additionally, Aureothin shows potential as a microbial biolarvicide, offering applications in ecological studies involving pest control and microbial interactions. -
HIV-1 Inhibitor
HIV-1 inhibitor-42 is a potent inhibitor of HIV-1 with an IC50 of 0.06 μM. This compound exerts its antiviral effects by targeting HIV-1 reverse transcriptase, inhibiting both RNA-dependent DNA polymerase and DNA-dependent DNA polymerase activities, with IC50 values of 0.518 μM and 0.072 μM, respectively. It serves as a valuable tool for studying HIV-1 replication and for the development of antiviral therapies. -
HIV-1 Inhibitor
HIV-IN peptide is a competitive inhibitor of HIV-1 protease, exhibiting an inhibitory constant (Ki) of 50 nM. This peptide plays a crucial role in the study of HIV-1 replication by disrupting the proteolytic processing of viral proteins. It is primarily utilized in research applications focused on antiviral drug development and the understanding of HIV biology. -
HIV-1 protease Inhibitor
U-96988 is a non-peptide inhibitor targeting HIV-1 protease, exhibiting a Ki value of 38 nM. It also demonstrates effectiveness against HIV-2 protease, with an IC50 value of 5 μM for the HIV-1IIIB strain. This compound serves as a valuable tool for research focused on HIV infection and protease inhibition mechanisms. -
HIV-1 Protease Inhibitor
Droxinavir is an HIV-1 protease inhibitor that specifically targets the S2 and S2' subsites of the HIV-1 protease enzyme. By binding to these sites, it interferes with the enzyme's function, preventing viral replication. The presence of the N88S mutation in the protease can confer resistance to Droxinavir, making it an important compound for investigating viral resistance mechanisms. This reagent is suitable for research applications related to human immunodeficiency virus type 1 infection and antiviral drug development. -
HIV-1 Protease Inhibitor
L-739594 is an HIV-1 protease inhibitor with a reported IC50 of 1.8 nM. It effectively inhibits the activity of the viral protease, impairing HIV replication. This compound is valuable for research applications aimed at studying HIV-1 biology and developing antiviral therapeutics. -
HIV-1 Fusion Inhibitor
Tifuvirtide (T-1249) is a synthetic peptide that acts as an HIV-1 fusion inhibitor by targeting the viral envelope glycoproteins to prevent entry into host cells. It exhibits potent antiretroviral activity, making it a valuable tool for studying HIV infection dynamics and therapeutic interventions. This compound is primarily utilized in research settings focused on HIV/AIDS pathogenesis and the development of novel antiviral strategies. -
HIV Inhibitor
(-)-Lentiginosine is an HIV inhibitor that targets viral replication mechanisms. This compound exhibits significant antiviral activity, making it a valuable tool in HIV research. Its unique structure and mode of action provide insights into potential therapeutic strategies for managing HIV infections.
